Keno Gutierrez, PhD, MBA, currently Executive Investment Director, is responsible for Healthcare investments within M Ventures, the strategic venture capital fund of Merck KGaA, Darmstadt, Germany. He has served as Board of Director and Observer to the Board of several biotech companies including Xilio, DNA Script, Riffyn, Galecto, Immunitas, Inthera, iOnctura, ApoGen and iOmx.
Keno is a buy-side healthcare specialist with 20 years of experience spanning investing (private and public equities), corporate finance, management consulting, and medical research. Prior to joining M Ventures in 2017, Keno worked at Omega Funds, where he invested in public and private healthcare companies, participating in direct investments and secondaries. Before joining Omega in 2014, Keno work at Piper Jaffray’s Healthcare Investment Banking group, advising biopharma and medtech companies on corporate finance, cross-border M&A and licensing. Prior to joining Piper Jaffray in 2010, he spent four years as a consultant at IMS Health (IQVIA), advising pharma clients on portfolio strategy and commercial operations. Keno is a Fellow of the Royal Society of Medicine, holds a PhD in Genetics from University College in London and an MBA from INSEAD. His research in lipid metabolism has been published in the top scientific journal Nature.